EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.42
+2.98%Oct 8, 2026, 11:00 UTC
Editas Medicine, Inc. received approval to initiate its Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia.
Source:Sep 9, 2026, 13:00 UTC
Editas Medicine granted an inducement award to its newly appointed Chief Medical Officer, Daniel Ory, M.D., on September 9, 2026.
Source:Aug 5, 2026, 20:01 UTC
Editas Medicine announced that EDIT-401 is on track for CTN submission this month, with data update expected in Q1 2027.
Source:Aug 5, 2026, 20:01 UTC
Editas Medicine announced a recent financing that strengthens its capital position, extending cash runway into the second half of 2028.
Source:Aug 5, 2026, 20:01 UTC
Editas Medicine reported financial results for the second quarter of 2026 and provided business updates.
Source: